Company Overview
HeartSciences Inc. operates as a medical technology company dedicated to enhancing clinical utility through the application of artificial intelligence to electrocardiogram (ECG) data. The firm specifically develops AI-enhanced ECG solutions and algorithms designed to detect impaired cardiac relaxation or cardiac dysfunction, aiming to expand the diagnostic capabilities of standard heart rhythm monitoring. This entity functions within the Healthcare sector, specifically inside the Medical Devices industry, a segment characterized by high regulatory standards and a focus on patient diagnostics and therapeutic interventions. The company's current scale is reflected in a market capitalization of $7.17M and an annual revenue of $8,669, with a workforce consisting of 15 employees. These valuation and revenue figures indicate that the company is a very small-cap entity with a minimal operational footprint, suggesting it is in an early stage of development or commercialization where capital efficiency is prioritized over broad market penetration.
Financial Health
The financial performance of HeartSciences Inc. for the trailing twelve months shows a revenue of $8,669, which is significantly outweighed by a net income of $-8,485,301 and an EBITDA of $-7,768,315. The substantial gap between the negligible revenue and the massive net loss reveals a cost structure dominated by heavy investment in research, development, or operational expenses that far exceed current income generation capabilities. The company reported a free cash flow of $-4,213,324, indicating that its current operations are burning cash rather than generating liquidity, which constrains financial flexibility until significant revenue milestones are achieved. Profitability metrics are severely impacted, with a gross margin of 57.9% suggesting that the cost of goods sold is less than half of revenue, yet this is undermined by an operating margin of -89939.6% and a profit margin of 0.0%, both of which indicate that overhead and administrative costs are consuming the entire operating profit and resulting in no net profit. Regarding liquidity and leverage, the company holds $3.40M in cash against $3.87M in debt, resulting in a debt-to-equity ratio of 145.81, which characterizes the balance sheet as highly leveraged and reliant on equity rather than creditor financing. Short-term liquidity is assessed by a current ratio of 1.19, which indicates that the company possesses slightly more current assets than current liabilities, providing a modest but tight buffer for meeting immediate obligations. Finally, the return on equity stands at -382.3% and the return on assets is -73.5%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently to generate positive returns.
Valuation Assessment
Valuation multiples for HeartSciences Inc. reflect its status as a pre-profitability entity, evidenced by a P/E ratio (TTM) of N/A and a forward P/E of -0.80. The difference between a non-existent trailing P/E and a negative forward P/E implies that the market is pricing in a scenario where earnings are expected to be negative or non-existent in the near term, making traditional earnings-based valuation models inapplicable. The price-to-book ratio is 2.70, which indicates that the market is valuing the company at a premium of 2.7 times its book value, a metric often seen in high-growth or technology firms where intangible assets like intellectual property may exceed recorded book value. Alternative valuation metrics provide further context, with a price-to-sales ratio of 826.57 and an EV/EBITDA of -0.98, suggesting that the market is willing to pay a massive multiple for sales revenue despite the lack of profitability or positive cash conversion. Price action over the past year has been volatile, with a 52-week high of $6.47 and a 52-week low of $2.01; without a specific current price provided in the facts, the stock trades somewhere within this range, exhibiting the typical characteristics of a small-cap biotech or medtech stock. The beta value of 2.54 indicates that the stock's price volatility is significantly higher than the broader market, meaning it is expected to move with greater intensity than the S&P 500 during periods of market stress or rally.
Growth & Income
Growth metrics for HeartSciences Inc. are listed as N/A for both revenue growth (YoY) and earnings growth (YoY), which explains why earnings are neither growing faster nor slower than revenue due to the lack of historical comparative data available. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that the firm does not distribute cash to shareholders and instead retains all available capital. This strategy implies that the company reinvests its earnings—or rather, its cash reserves—into growth initiatives such as R&D, regulatory approvals, or market expansion rather than paying dividends to income-seeking investors. The overall growth and income profile is defined by a complete absence of current profitability and a reliance on external capital or existing cash reserves to fund operations while pursuing long-term development goals for its AI-ECG technology.